Castle Biosciences (CSTL) Current Leases (2021 - 2026)

Castle Biosciences has disclosed Current Leases across 6 years of filings, most recently posting $1.3 million for Q1 2026.

• Current Leases for Q1 2026 came in at $1.3 million, down 12.61% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.3 million (down 12.61% YoY), and the FY2025 annual result was $1.3 million, down 20.42% from the prior year.
• Current Leases came in at $1.3 million for Q1 2026 at Castle Biosciences, down from $1.3 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $2.0 million in Q2 2023 to a low of $1.1 million in Q3 2023.
• The 5-year median for Current Leases is $1.4 million (2025), against an average of $1.4 million.
• Across the five-year window, Current Leases soared 62.35% in 2023 and slumped 37.64% in 2024, its largest moves.
• Castle Biosciences' Current Leases stood at $1.8 million in 2022, then plunged by 36.02% to $1.1 million in 2023, then surged by 46.44% to $1.7 million in 2024, then dropped by 20.42% to $1.3 million in 2025, then declined by 5.36% to $1.3 million in 2026.
• The last three Current Leases figures came in at $1.3 million (Q1 2026), $1.3 million (Q4 2025), and $1.4 million (Q3 2025), per Business Quant data.